open access

Vol 18, No 2 (2015)
Original articles
Published online: 2015-07-31
Submitted: 2015-07-31
Accepted: 2015-07-31
Get Citation

Long bone metastases as predictors of survival in patients with metastatic renal cancer

Agnieszka Giżewska, Ewa Witkowska-Patena, Zofia Stembrowicz-Nowakowska, Andrzej Mazurek, Sebastian Osiecki, Łukasz Kowalski, Mirosław Dziuk, Marta Slomka
DOI: 10.5603/NMR.2015.0021
·
Pubmed: 26315869
·
Nucl. Med. Rev 2015;18(2):89-91.

open access

Vol 18, No 2 (2015)
Original articles
Published online: 2015-07-31
Submitted: 2015-07-31
Accepted: 2015-07-31

Abstract

BACKGROUND: The aim of this study was to assess the prevalence of long bone metastases in renal cancer patients and to evaluate their utility as predictors of survival in this group.

MATERIAL AND METHODS: This retrospective study included 20 patients with metastatic renal cancer and bone metastases. The patients were referred for regular bone scintigraphy in order to assess disease spread in the skeleton. The patients were divided into two groups: those with 1) metastases in the skeleton (including long bones) and those with 2) metastases in the axial skeleton only.

RESULTS: Bone scintigraphy imaging was performed regularly up to 81 months from the first positive bone scan. During that time 11 deaths (8 among patients with long bone lesions) were recorded. Kaplan-Meyer curves showed that patients with long bone metastases tend to have lower survival probability in comparison to the ones with metastases in other bones.

CONCLUSIONS: Bone metastases localization seems to influence survival in patients with renal cancer. Long bone-involving spread of the disease is associated with worse survival probability than the spread to the other bones.

Abstract

BACKGROUND: The aim of this study was to assess the prevalence of long bone metastases in renal cancer patients and to evaluate their utility as predictors of survival in this group.

MATERIAL AND METHODS: This retrospective study included 20 patients with metastatic renal cancer and bone metastases. The patients were referred for regular bone scintigraphy in order to assess disease spread in the skeleton. The patients were divided into two groups: those with 1) metastases in the skeleton (including long bones) and those with 2) metastases in the axial skeleton only.

RESULTS: Bone scintigraphy imaging was performed regularly up to 81 months from the first positive bone scan. During that time 11 deaths (8 among patients with long bone lesions) were recorded. Kaplan-Meyer curves showed that patients with long bone metastases tend to have lower survival probability in comparison to the ones with metastases in other bones.

CONCLUSIONS: Bone metastases localization seems to influence survival in patients with renal cancer. Long bone-involving spread of the disease is associated with worse survival probability than the spread to the other bones.

Get Citation

Keywords

renal cancer, bone metastases, survival, prognostic factor

About this article
Title

Long bone metastases as predictors of survival in patients with metastatic renal cancer

Journal

Nuclear Medicine Review

Issue

Vol 18, No 2 (2015)

Pages

89-91

Published online

2015-07-31

DOI

10.5603/NMR.2015.0021

Pubmed

26315869

Bibliographic record

Nucl. Med. Rev 2015;18(2):89-91.

Keywords

renal cancer
bone metastases
survival
prognostic factor

Authors

Agnieszka Giżewska
Ewa Witkowska-Patena
Zofia Stembrowicz-Nowakowska
Andrzej Mazurek
Sebastian Osiecki
Łukasz Kowalski
Mirosław Dziuk
Marta Slomka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl